
Loading, please wait...

Loading, please wait...

This study analyzed 778 metastatic breast cancer (MBC) patients (155 with bone-only [BO]-MBC) to assess circulating tumor DNA (ctDNA) tumor fraction (TF) as a prognostic marker. Detectable ctDNA was equally likely in BO-MBC and non-BO MBC. Importantly, for BO-MBC patients, a TF of <1% was associated with significantly better real-world overall survival compared to intermediate or high TF. This suggests TF is a prognostic indicator even in BO-MBC.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This study analyzed 778 metastatic breast cancer (MBC) patients (155 with bone-only [BO]-MBC) to assess circulating tumor DNA (ctDNA) tumor fraction (TF) as a prognostic marker. Detectable ctDNA was equally likely in BO-MBC and non-BO MBC. Importantly, for BO-MBC patients, a TF of <1% was associated with significantly better real-world overall survival compared to intermediate or high TF. This suggests TF is a prognostic indicator even in BO-MBC.
Yesterday

Researchers at SGPGIMS Lucknow have isolated and cultured human heart valve interstitial cells from donor tissues. This milestone advances understanding of rheumatic heart disease pathways like TGF-beta/SMAD3 and ERK1/2, laying the foundation for tissue-engineered heart valves and drug testing.
Today

A study identifies a critical hypospadias gene-environment interaction. Research shows that the risk gene DNAH8 and DEHP exposure combine to disrupt steroidogenesis and mesenchymal progenitor cell differentiation, significantly increasing the risk of severe urethral malformations in male fetuses.
6 days back

A pre-clinical study reveals that elevated serum pro-N-cadherin levels correlate strongly with severe cardiac fibrosis and diastolic dysfunction following radiation exposure, promising a potential early biomarker for radiation-related heart disease.
4 days back

Researchers at Kyushu University have uncovered a novel compound, lipoic acid trisulfide (LASSS), that enhances hepatocyte growth factor (HGF) signaling and protects against nitration-induced protein dysfunction, presenting a potential breakthrough for age-related muscle atrophy and sarcopenia.
3 days back

Deepinder Goyal's healthtech startup Temple is raising capital at a $500 million valuation and pricing its temporal wearable at Rs 80,000. Worn on the side of the forehead, the device tracks microvascular blood flow and real-time Entropy to monitor physiological stress, metabolic expenditure, and recovery.
Today